Phosphorylated Tau Levels in Donated Blood
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT07157839
- Status
- Recruiting
Conditions
- Alzheimer&Amp;#39;s Disease
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Study Details
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Key Dates
- Start date
- Aug 28, 2025
- Status verified
- Feb 2026
- Primary completion
- Nov 1, 2026
- Completion
- Nov 1, 2026
Study Design
- Enrollment
- 250 participants (estimated)
Primary Outcome Measure
Tau and pTau [ Time Frame: 6 months. ]
Central Contacts
- Zhongcong Xie, M.D., Ph.D.17135006207
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | Xian Li, M.D. (SUB_INVESTIGATOR) Hlaing Tint, M.D. (SUB_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's PatientsRecruiting · University of Arizona · Tucson, Arizona